

Haematologica  
HAEMATOL/2020/254482  
Version 1

Mysteries of partial DHODH inhibition and leukemia  
terminal-differentiation

Yogen Saunthararajah

Disclosures: Although not directly pertinent to this manuscript, in the interests of full disclosure, Yogen Saunthararajah has issued patents around tetrahydrouridine and decitabine, ISWI family inhibition and cancer differentiation inducers, and has equity, consulting and Board interest in EpiDestiny, that has licensed oral tetrahydrouridine-decitabine